[{"orgOrder":0,"company":"Berkeley Lights","sponsor":"Ablexis","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Ablexis, AlivaMab Discovery Services, and Berkeley Lights Collaborate to Identify a Diverse Panel of Anti-SARS-CoV-2 Human Antibodies","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical"},{"orgOrder":0,"company":"Berkeley Lights","sponsor":"Abveris","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Abveris Announces Antibody Discovery Agreement with Immunitas Using the Berkeley Lights Beacon\u00ae","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Large molecule","productStatus":"Undisclosed","date":"October 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery"}]
Find Clinical Drug Pipeline Developments & Deals by Berkeley Lights
Abveris will utilize its proprietary DiversimAbTM mouse model in combination with its next-generation B cell screening platform, powered by the Berkeley Lights Beacon®, to rapidly discover monoclonal antibodies for use as research reagents and therapeutics for immuno-oncology.
The companies together have generated and recovered sequences encoding a rich panel of human antibodies against the S1 spike protein of the SARS-CoV-2 virus.